Skip to content
The challenge of preventing pharmacy benefit managers (PBMs) from driving up drug prices was front and center on Capitol Hill this week. Bipartisan legislation […]
Congress puts PBMs in the spotlight during a busy week on Capitol Hill Read More »
With the deadly threat of drug-resistant infections increasing daily, we desperately need actions to address the broken commercial marketplace for novel antimicrobials—including the PASTEUR
Legislation to fight AMR superbugs is an urgent need, BIO member tells Senate hearing Read More »
The Senate Health, Education, Labor, and Pensions (HELP) Committee released a bipartisan discussion draft of the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization bill
Senate HELP’s PAHPA draft: The good, the bad, and the ugly Read More »
The U.S. Food and Drug Administration (FDA) granted traditional approval to the groundbreaking Alzheimer’s drug LEQEMBI, the first in a new class of Alzheimer’s
FDA grants traditional approval to LEQEMBI Read More »
After the Centers for Medicare & Medicaid Services (CMS) released its guidance for the Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction
BIO: New CMS guidance a ‘missed opportunity’ for future medical innovation, patients Read More »
The COVID-19 pandemic had a notably unprecedented impact on the world. Its lasting effects on society, economics, and healthcare have initiated a global discussion
5 lessons learned from COVID-19 Read More »
A June 21 House hearing on health care costs put a sharp focus on the need for transparency to prevent pharmacy benefit managers (PBMs)
House hearing puts focus on need for PBM transparency Read More »
On June 13, the House Energy & Commerce Health Subcommittee held a hearing, Legislative Solutions to Bolster Preparedness and Response for All Hazards and
BIO’s Phyllis Arthur testifies on need to reauthorize PAHPA, pass PASTEUR Act Read More »
Lawsuits filed in early June by Merck & Co. and the U.S. Chamber of Commerce seek to halt drug price controls established by the
Merck and U.S. Chamber file lawsuits to block IRA’s drug price controls Read More »
The Inflation Reduction Act (IRA) will introduce arbitrary changes in drug development as pharma companies are forced to work with complex new regulations that
BIO panels break down IRA’s challenges for drug makers and patients Read More »
